Amneal Pharmaceuticals, Inc. - Class A Common Stock, par value $0.01 (AMRX)

Historical Holders from Q2 2018 to Q3 2025

Symbol: AMRX on Nasdaq
Type / Class: Equity / Class A Common Stock, par value $0.01
Shares outstanding: 315,976,000
All holders as of 30 Sep 2025: Q3 2025
Total 13F shares, excl. options: 149,537,932
Holdings value: $1,497,239,394
% of all portfolios: 0.003%
Number of holders: 243
Number of buys: 131
Number of sells: -103
Average buys %: +0%
Average sells %: -0%

Reported Shares, Excluding Options vs Price

Reported Value, Excluding Options

Total Investors

Significant Owners of Amneal Pharmaceuticals, Inc. - Class A Common Stock, par value $0.01 (AMRX)

Filer	Ownership	Change %	Holdings Value	Nb Shares	Change %	Reporting Name	Report Period
Patel Tushar Bhikhubhai	15.7%		$363,365,003	48,578,209		Patel Tushar Bhikhubhai	14 Mar 2025
Patel Chintu	8.2%		$259,359,420	25,910,032		Patel Chintu	03 Oct 2025
Patel Dipan	7.6%	-1.2%	$238,528,210	23,828,992	0%	Patel Dipan	03 Oct 2025
Patel Chirag K.	7.1%		$179,439,606	22,180,421		Patel Chirag K.	06 Aug 2025
Mahesh Akram	6.56%		$153,779,517	20,558,759		Akram Mahesh	31 Mar 2025
VANGUARD GROUP INC	5.02%		$117,905,198	15,762,727		The Vanguard Group	31 Mar 2025

Institutional Holders of Amneal Pharmaceuticals, Inc. - Class A Common Stock, par value $0.01 (AMRX)

Period	Reported Shares, Excl. Options	Value, Excl. Options	Change	Puts Notional Value	Calls Notional Value	Price	Investors
2025 Q3	149,537,932	$1,497,239,394	+$80,964,118	$0	$3,577,574	$10.01	243
2025 Q2	141,656,835	$1,146,033,099	+$54,531,142	$398,837	$1,572,696	$8.09	237
2025 Q1	134,631,456	$1,128,246,067	+$84,513,755	$860,626	$2,527,408	$8.38	232
2024 Q4	125,924,024	$997,296,789	-$136,424,861	$1,117,512	$2,867,040	$7.92	194
2024 Q3	142,604,811	$1,186,537,394	+$32,304,784	$407,680	$474,240	$8.32	180
2024 Q2	138,637,695	$880,361,225	+$192,128,358	$291,465	$1,487,805	$6.35	179
2024 Q1	108,100,411	$655,086,509	-$6,545,489	$496,314	$1,999,194	$6.06	173
2023 Q4	109,241,884	$663,112,026	+$52,701,039	$92,264	$945,706	$6.07	151
2023 Q3	101,896,343	$430,042,448	+$19,693,333	$7,596	$427,486	$4.22	141
2023 Q2	97,368,877	$301,754,419	+$4,221,215	$117,490	$308,450	$3.1	122
2023 Q1	96,883,833	$134,657,443	-$8,205,387	$27,661	$56,990	$1.39	142
2022 Q4	101,876,885	$202,739,453	+$4,463,674	$73,232	$95,520	$1.99	155
2022 Q3	99,522,767	$201,053,119	-$1,681,376	$174,000	$368,000	$2.02	144
2022 Q2	99,362,374	$315,991,849	-$2,095,558	$333,000	$456,000	$3.18	140
2022 Q1	100,125,536	$417,146,539	-$2,779,055	$1,348,000	$630,000	$4.17	154
2021 Q4	100,743,592	$481,044,810	-$750,941	$1,253,000	$1,185,000	$4.79	148
2021 Q3	100,372,906	$535,260,080	+$2,515,423	$2,192,000	$2,295,000	$5.34	150
2021 Q2	99,933,342	$511,565,477	-$13,076,955	$1,609,000	$1,368,000	$5.12	153
2021 Q1	101,580,612	$683,525,934	+$24,752,974	$1,749,000	$2,117,000	$6.73	155
2020 Q4	99,489,363	$454,601,386	-$9,010,325	$985,000	$1,539,000	$4.57	128
2020 Q3	101,459,246	$393,634,017	-$1,370,007	$453,000	$1,320,000	$3.88	133
2020 Q2	101,691,059	$484,034,077	+$16,566,905	$876,000	$1,679,000	$4.76	131
2020 Q1	98,300,162	$342,039,040	-$17,271,636	$470,000	$164,000	$3.48	117
2019 Q4	101,152,211	$487,526,241	-$9,606,036	$499,000	$2,000	$4.82	116
2019 Q3	108,293,336	$314,077,694	-$45,957,076	$585,000	$0	$2.9	111
2019 Q2	105,380,317	$755,561,286	-$88,067,679	$405,000	$658,000	$7.17	116
2019 Q1	109,021,244	$1,544,805,998	-$98,023,386	$184,000	$1,020,000	$14.17	150
2018 Q4	116,187,735	$1,572,087,804	+$89,696,977	$0	$1,588,000	$13.53	157
2018 Q3	108,476,937	$2,407,193,089	+$282,716,887	$235,000	$888,000	$22.19	162
2018 Q2	97,469,656	$1,599,487,071	+$1,599,409,043	$322,000		$16.41	163